吉利德科学Gilead Sciences (GILD) 2015年年度报告「NASDAQ」.pdf

1、GILEAD ANNUAL REPORT 2015Gilead achieved record total revenue of$32.6 billion in 2015,with marked progress across our portfolio of products and pipeline.The company returned about three-quarters of free cash flow to investors as it issued its first-ever quarterly cash dividend and increased the stoc

2、k buy-back program.The company also expanded its global reach and today more than 8,000 employees across six continents are working together and with Gileads partners to help millions of patients around the world.Working Toward the Next Generation of HIV CareFor more than 25 years,Gilead has led the

3、 development of antiviral therapy for HIV/AIDS,helping to transform HIV infection from a fatal and debilitating disease into a chronic,manageable condition.The availability of HIV therapies has helped avert an estimated 7.8 million AIDS deaths since 2000.In 2015,Gileads HIV products were prescribed

4、for more than 70 percent of newly-diagnosed HIV patients in the United States.In Europe,7 out of 10 patients started on a regimen with a Truvada backbone.While exceptional progress has been made in the field of HIV,there is still a growing need for new treatment options to improve the health of peop

5、le as they age with the disease.To help provide this much needed new option,Gilead has been studying an innovative nucleotide called tenofovir alafenamide(TAF)as an alternative to tenofovir disoproxil fumarate(TDF)the active ingredient in Viread and a component of Truvada,Atripla,Complera and Stribi

6、ld.TAF has demonstrated high antiviral efficacy and improved laboratory markers of renal and bone safety compared to TDF in clinical trials in combination with other antiretroviral agents.In November,Genvoya,the companys first TAF-based single tablet regimen(STR)for the treatment of HIV-1 infection,